1. ALLA AKTIER
  2. NYHETER
  3. ZICCUM

Ziccum

Nyheter Ziccum Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Ziccum CEO holds a Q&A session regarding current activities and dialogues

Ziccum’s CEO, Ann Gidner, in Questions & Answers session moderated by analyst Jonathan Furelid.

Ann Gidner joins Jonathan Furelid in a Q&A session providing more background regarding on-going Ziccum activities and business dialogues. The questions, nicely curated by Ziccum shareholders, are addressing topics including technology and business development, scientific milestones, resource allocation, and soft funding opportunities.

You may access the recorded session here: https://youtu.be/OIdwath65Qc

For more information about Ziccum, please contact:

Ann Gidner
CEO, Ziccum AB
Mail: gidner@ziccum.com
Mobile: +46 722140141

Jonas Ekblom
Chairman of the Board, Ziccum AB
Mail: ekblom@ziccum.com
Mobile: +46 736777540

Ziccum’s Certified Adviser is
Vator Securities AB

About Ziccum

Ziccum is developing LaminarPace®, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPace® uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

Attachments

Ziccum CEO holds a Q&A session regarding current activities and dialogues

Datum 2024-11-27, kl 09:00
Källa MFN
Bifogade filer
Ziccum CEO holds a Q&A session regarding current activities and dialogues